TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2859.
Locate Jan Aushadhi KendraClinical Overview
Telmisartan and Metoprolol Succinate (Extended-Release) combines an ARB with a cardioselective beta-1 adrenergic blocker. Telmisartan reduces afterload and inhibits vascular remodeling, while extended-release metoprolol attenuates sympathetic nervous activity, reduces resting and exercise heart rates, lowers myocardial oxygen demand, and stabilizes cardiac rhythm. Indicated for hypertension associated with coronary artery disease, stable angina, post-myocardial infarction, or resting tachycardia.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with a glass of water, with or immediately after food. Swallow whole; do not crush or chew extended-release tablets. Never discontinue abruptly; taper gradually over 1-2 weeks.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Bradycardia (slow heart rate), dizziness, fatigue, cold extremities, hypotension, mild shortness of breath. Rare/Severe: Boxed warning: Exacerbation of angina/myocardial infarction upon abrupt cessation; fetal toxicity, heart block, and bronchospasm in asthmatics.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning: Abrupt cessation can precipitate severe angina, ventricular arrhythmias, or myocardial infarction. Black box warning for fetal toxicity. Contraindicated in severe bradycardia, second- or third-degree AV block, and cardiogenic shock.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Metoprolol Tablets 25 mg
Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.
Metoprolol Extended release Tablets 50mg
Beta-adrenergic receptor antagonist (cardioselective beta-1 blocker, non-selective beta blocker, or third-generation vasodilating beta-blocker with alpha-blockade or nitric oxide release) on the WHO Model List of Essential Medicines. It competitively blocks adrenergic stimulation, reducing heart rate, myocardial contractility, cardiac output, and renin release. Indicated for hypertension, stable angina pectoris, heart failure, cardiac arrhythmias, and post-myocardial infarction secondary prevention.
Telmisartan 40mg + Hydrochlorothiazide 12.5mg Tablets
Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.
Telmisartan Tablets 20mg
Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.